Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 6, 2004, Pages 1043-1048

  Cruden, Nicholas L M ^a   Witherow, Fraser N ^a   Webb, David J ^a   Fox, Keith A A ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

ACE inhibitors; Bradykinin; Heart failure; Hemodynamics; Pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; B 9340; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ ANTAGONIST; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; NITRATE; PLACEBO; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; ENZYME INHIBITOR INTERACTION; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART OUTPUT; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BRADYKININ; CARDIAC OUTPUT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; FOREARM; HEART FAILURE, CONGESTIVE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; LOSARTAN; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, ANGIOTENSIN; RECEPTORS, BRADYKININ; REGIONAL BLOOD FLOW; VASODILATION;

EID: 2942516035     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000129331.21092.1d     Document Type: Article

References (35)

1. Powers ER, Bannerman KS, Stone J, Reison DS, Escala EL, Kalischer A, Weiss MB, Sciacca RR, Cannon PJ. The effect of captopril on renal, coronary, and systemic hemodynamics in patients with severe congestive heart failure. Am Heart J. 1982;104:1203-1210.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
3. Erdös EG, Yang HYT. An enzyme in microsomal fraction of kidney that inactivates bradykinin. Life Sci. 1967;6:569-574.
4. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem. 1993;268:9496-9503.
5. Bonner G, Preis S, Schunk U, Toussaint C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol. 1990;15:S46-S56.
6. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci. 1994;87:567-574.
7. Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989;412:543-555.
8. Kuga T, Mohri M, Egashira K, Hirakawa Y, Tagawa T, Shimokawa H, Takeshita A. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol. 1997;30:108-112.
9. Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol. 2002;40:961-966.
10. Stewart JM, Gera L, Chan DC, Whalley ET, Hanson WL, Zuzack JS. Potent, long-acting bradykinin antagonists for a wide range of applications. Can J Physiol Pharmacol. 1997;75:719-724.
11. 2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation. 2000;102:2190-2196.
12. 2-receptor antagonist. Br J Clin Pharmacol. 1994;38:317-321.
13. 1 receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res. 2000;48:194-210.
14. 1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 2002;105:627-632.
15. 9-bradykinin in human coronary arteries. Br J Pharmacol. 1995;116:3083-3085.
16. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
17. 2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension. 2000;36:132-136.
18. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation. 2001;104:2177-2181.
19. Davie AP, Dargie HJ, McMurray JJ. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation. 1999;100:268-273.
20. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstan MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagaran B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
21. Witherow FN, Dawson P, Ludlam CA, Webb DJ, Fox KA, Newby DE. Bradykinin receptor antagonism and endothelial tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol. 2003;23:1667-1670.
22. Holmquist B, Bunning P, Riordan JF. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem. 1979;95:540-548.
23. Morton JJ, Webb DJ. Measurement of plasma angiotensin II. Clin Sci. 1985;68:483-484.
24. Abrams WB, Davies RO, Gomez HJ. Clinical pharmacology of enalapril. J Hypertens. 1984;2:S31-S36.
25. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 1993;35:290-297.
26. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med. 2002;113:409-418.
27. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999;82:57-61.
28. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol. 2001;37:1056-1061.
29. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
30. McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
31. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
32. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol. 1994;24:67-73.
33. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 2003;107:579-585.
34. Tsutsumi Y, Matsubara H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilatation. J Clin Invest. 1999;104:925-935.
35. 2-receptor- dependent mechanism. Hypertension. 2003;41:1092-1095.